Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
PMI vs DCTH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)
DCTH Overall Winner
6-Pillar Tally: PMI 0 – 6 DCTH
Matrix Metrics: PMI 2 – 8 DCTH
As of Nov 19, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas DCTH carries 35.4/100 (SELL) at $19.24 (70.3x Forward P/E, 5.2% operating margin).
- Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. DCTH 35.4/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -248.1% operating margin) and revenue trajectory (+70.7% vs. +38.6% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About PMI vs DCTH
PMI
Picard Medical, Inc.
$6.30
-2.17% 1D
Market Cap
$17.1M
TTM Revenue
$6.3M
Forward P/E
N/M
Beta / 30D Vol
54.06β · 134% Vol
Unified Composite Score
48.4
HOLD
Tech 39.0
Fund 45.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
DCTH
Head-to-Head Winner
Delcath Systems Inc
$19.24
-2.34% 1D
Market Cap
$685.3M
TTM Revenue
$110M
Forward P/E
70.3x
Beta / 30D Vol
1.64β · 130% Vol
Unified Composite Score
35.4
SELL
Tech 50.0
Fund 36.0
Flow 73.0
Mom 44.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (PMI 0 – 6 DCTH)
1. Valuation Multiples
DCTH
Forward P/E
N/M
70.3x
Trailing P/E
2.9x
123.1x
PEG Ratio
N/M
1.60x
EV / Revenue
3.2x
5.7x
2. Growth & Scale
DCTH
Revenue Growth (YoY)
+38.6%
+70.7%
Earnings Growth (YoY)
+0.0%
+750.0%
TTM Revenue (USD)
$6.3M
$110M
Market Cap
$17.1M
$685.3M
3. Profitability & Quality
DCTH
Gross Margin
18.6%
87.6%
Operating Margin
-248.1%
5.2%
Net Profit Margin
0.0%
6.0%
Return on Equity (ROE)
0.0%
5.4%
4. Balance Sheet & Cash Flow
DCTH
Cash Generation (TTM)
-$17M
$20M
Cash Flow Margin
N/A
18.3%
Net Cash / Leverage
$3.2M Net Debt
$53M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
DCTH
Options Structure Phase
UNCLASSIFIED
BREAKOUT
Current IV / %ile
N/A (N/A)
73.8% (29th %ile)
Put/Call OI Skew
N/A
0.21x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat
DCTH
OpEx & R&D Intensity
N/A
82.4% of Rev ($91M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PMI (2) vs DCTH (8)| Institutional Metric | PMI | DCTH | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $17.1M | $685.3M | DCTH | |
| Trailing P/E Ratio | 2.9x | 123.1x | PMI | |
| Forward P/E Ratio | N/M | 70.3x | DCTH | |
| Revenue Growth (YoY) | +38.6% | +70.7% | DCTH | |
| Operating Margin (TTM) | -248.1% | 5.2% | DCTH | |
| Net Profit Margin | 0.0% | 6.0% | DCTH | |
| Return on Equity (ROE) | 0.0% | 5.4% | DCTH | |
| 52-Week Range Position | 34% ($0–$18) | 77% ($8–$23) | DCTH | |
| Beta / 30D Volatility | 54.06β · 134% Vol | 1.64β · 130% Vol | DCTH | |
| Unified Institutional Score | 48.4 / 100 (HOLD) | 35.4 / 100 (SELL) | PMI | |
| Trailing 12M Revenue (USD) | $6.3M | $110M | Scale | |
| Gross Profit Margin (TTM) | 18.6% | 87.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.2x EV/Rev | 1.60x PEG · 5.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$17M ($3.2M Net Debt) | $20M ($53M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DCTH +65.46 pp
3M Horizon
PMI +84.01 pp
6M Horizon
PMI +3369.67 pp
1Y Horizon
PMI +25.6 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PMI Revenue | DCTH Revenue | PMI Op. Margin | DCTH Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2013 | N/A | $0M | N/A | -4179.6% | DCTH |
| FY2014 | N/A | $0M | N/A | -1805.8% | DCTH |
| FY2015 | N/A | $0M | N/A | -870.6% | DCTH |
| FY2021 | N/A | $0M | N/A | -690.0% | DCTH |
| FY2022 | N/A | $0M | N/A | -1245.1% | DCTH |
| FY2023 | N/A | $0M | N/A | -1849.0% | DCTH |
| FY2024 | $0M | $40M | -312.3% | -33.4% | DCTH |
| FY2025 | $0M | $90M | -268.4% | 0.8% | DCTH |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
PMI
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DCTH
BREAKOUT
Current IV
73.8%
IV Percentile
29th %ile
Put/Call OI Skew
0.21x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
PMI Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
DCTH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
82.4% of Rev ($91M)
90D Engineering Disclosures
0 Published
Investor FAQ PMI vs DCTH Key Questions & Quantitative Answers
As of Nov 19, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas DCTH carries 35.4/100 (SELL) at $19.24 (70.3x Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. DCTH 35.4/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -248.1% operating margin) and revenue trajectory (+70.7% vs. +38.6% YoY).
DCTH leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), PMI cumulative revenue shifted N/A while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.
DCTH screens cheaper on headline valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas DCTH trades at 70.3x Forward P/E, 123.1x Trailing P/E, 1.60x PEG, and 5.7x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus DCTH (5.4% ROE) capital efficiency.
In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, DCTH carries 73.8% implied volatility (29th %ile, Balanced (25th–60th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (1.64β · 130% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DCTH vs PMI · Reverse Pair
PMI vs RDN
· Sector Peer
PMI vs MTG
· Sector Peer
PMI vs MBI
· Sector Peer
DCTH vs CRMD
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma